Environmental Markets for Biotechnology
U.S. sales of environmental biotechnology products was valued at $241.2 million in 2012. This is expected to increase at a total compound annual growth rate (CAGR) of 7.9%, with 2013 sales of $261.9 million, rising to $382.3 million in 2018.
- An overview of the market for environmental biotechnology products and their utilization in a variety of waste treatment markets.
- Analyses of global market trends, with data from 2010 through 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
- Descriptions of various types of environmental biotechnology products, including microbial blends, nutrients, enzymes, and microbes.
- Examination of the environmental biotechnology industry on a worldwide basis from an application perspective.
- Detailed information on manufacturers; academic, and commercial developments; and innovative end-use biofuel products.
- Comprehensive company profiles of major product manufacturers.
This study contains comprehensive data concerning the products and applications involved in the use of microorganisms, enzymes and nutrients for waste treatment. This study will give insightful information from the perspective of the manufacturer and customer. Major product manufacturers are profiled and application markets are extensively reviewed. Detailed forecasts and analysis provide comprehensive market information on product sales, application markets and customers, potential end-use biofuel production and international opportunities.
Applications for wastewater treatment and bioremediation processes along with other treatment markets will be studied with information about current and future needs. A review of historical and current significance of government regulations, patents, and research and development will show how the market dynamics of environmental management affect future product sales. Also, the growing international markets for microorganism, enzyme and nutrient products will be listed. Information concerning U.S. exports and leading international companies will be analyzed.
Jon Evans has been involved in business development and research for the medical industry since 1984. Evans' career includes four years as a diagnostic systems sales representative and more than 15 years in market research and strategy analysis with Fortune 500 clients. He has developed expertise in assessing the unique business development challenges facing firms in the medical industry and designing strategies to optimize market performance. Mr. Evans received a B.S. in biology from Rutgers University in 1983, and an MBA in business analysis from San Francisco State University in 1989.